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Chapter 1: Introduction and Background 
1. 1 Introduction 
1.1.1 Importance of EHR Data.  
Prior to the implementation and use of EHRs, claims data has traditionally been used as 
the main source of electronic health information to support clinical research. It is limited 
however, since claims data are missing many key data elements that are required to better 
reflect the patient’s conditions and care plan [1]. It only captures demographics, 
diagnoses and procedures recorded for billing purposes  [2]. To fill in this knowledge 
gap, EHRs can provide important details about vital signs, diagnostic test results, social 
and family history, prescriptions and physical examination findings. Perhaps one main 
advantage of claims data over EHRs is that it is only through claims data that a holistic 
view of the patient’s interactions with the health care system can be seen given that only 
57% of healthcare providers utilized EHRs in 2011 [3, 4]. The current trend is to utilize 
EHRs to generate and test hypotheses about the relationships among patients, diseases, 
practice styles, therapeutic modalities and clinical outcomes [5, 1, 2]. 
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1.1.2 Importance of Pharmacy Information.  
Medication information is among the most important types of clinical data in EHR. It is 
critical for healthcare safety and quality, as well as for clinical research that uses EHR 
Data [6]. Medication orders are often represented by two parts; medication name and 
medication signature (information about drug administration, such as dose, route, 
frequency, and duration). [7]. Sharing medication names and signatures among providers 
is necessary to create an accurate medication profile for a patient [6]. It is also an 
essential step for the support of accurate medication reconciliation process; which 
compares a patient's medication orders to all of the medications that the patient has been 
taking to avoid medication errors such as omissions, duplications, dosing errors, or drug 
interactions [8]. This has the potential to reduce adverse drug reactions (ADR); which is 
one of the leading causes of morbidity and mortality in health care [9]. The Institute of 
Medicine reported in January of 2000 that from 44,000 to 98,000 deaths occur annually 
from medical errors. Of this total, an estimated 7,000 deaths occur due to ADRs [10].  
To facilitate sharing of EHR medication data, medication terminology and coding 
standards have been utilized. The National Library of Medicine (NLM) created RxNorm, 
a standardized nomenclature for clinical drugs that is used for the electronic exchange of 
medication name and signature, as well as other drug-related information [11]. The goal 
of RxNorm is to enable pharmacy management systems and drug interaction software, 
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using different drug nomenclatures, to share and exchange data efﬁciently by mapping 
their drug vocabularies to standard RxNorm clinical drug names. The scope of RxNorm 
contains the names of prescription and many over-the-counter drugs available in the 
United States. Radiopharmaceuticals, bulk powders, contrast media, food, dietary 
supplements, and medical devices, such as bandages and crutches, are all out of scope for 
RxNorm [12]. 
To support accurate and efficient RxNorm encoding of EHR medications, medication 
names and signatures can be used [13,14]. The main drawback of using a medication 
name and signature alone for RxNorm coding is that the medication could be mapped to 
different RxNorm concept unique identifier (RxCUI) which would need further manual 
review by a domain expert to assign the right RxCUI to the medication order [13]. 
Therefore, EHR medication orders usually populate medication’s National Drug Code 
(NDC) at the time the order is being created and recorded by the system. A single NDC 
code is associated with only one single RxCUI but a single RxCUI is associated with 
multiple NDCs [15].   Drug NDC serves as a universal product identifier for drugs. 
Registered drug establishments regularly provides The Food and Drug 
Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, 
compounded, or processed by it for commercial distribution. The NDC is a commercially 
oriented coding system identifying the company, the drug trade name, strength, and 
dosage form and package size. [16]. 
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Studies have found that the NDC Directory is unreliable . A study in 2011 found that 
27% of the 123,856 codes in the NDC Directory were erroneous, and that 14,337 
additional prescription drug products were missing codes [17,18]. With missing or 
inaccurate NDCs, drug names and signatures would be employed for coding medication 
records. 
 
1.1.3 EHR Medication Data issues and Impact to Mapping and Usability.   
Medications orders in EHR databases are usually created using computer systems that 
populate medication information as well as NDC codes. However, there are cases where 
medication orders are missing key information such as an NDC code or any of the 
medication signature information at the time of data entry. For example, providers often 
use free text fields to store clinical drug data in electronic health records. The use of free 
text facilitates rapid data entry by the clinician. Errors in spelling, abbreviations, and 
jargon, however, limit the utility of mapping medications to RxNorm identifiers [19].  
Furthermore, patients’ self-reporting medications may have missing NDCs and 
incomplete data [20]. EHR data in general suffers from at least one of the three common 
data quality issues in Table (1) [21]. This might impact the quality and efficiency of 
automated RxNorm encoding tools [22, 23]. 
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Table 1 -EHR data quality issues 
Data Quality Issue Definition 
Incompleteness  Missing information 
Inconsistency  
Information mismatch between various or within the 
same EHR data source; 
Inaccuracy  
Non-specific, non-standards-based, inexact, incorrect, or 
imprecise information. 
 
 
EHR databases contain millions of medication orders that are coded to RxNorm using 
tools such as Medi-Span®, © First Databank, Drug Indications Database™ and RxNav (a 
browser for RxNorm by NLM) [24]. The accuracy of the automated mapping relies 
heavily on the completeness and uniqueness of the medication information (name, 
signature, and NDC). Due to missing information, the mapping task becomes suboptimal 
and cannot be fulfilled by only using an exact string match or simple mapping algorithm 
since this would have the potential to misrepresent the RxNorm dataset through the 
mapping to many target RxNorm concepts [25]. Manual mapping would also be costly 
and time consuming.  Little research has been done to study the mapping between 
RxNorm and EHR medication orders developed. Such studies are critical for the future 
adoption and integration of RxNorm in EHRs [23].  
In this thesis, the impact of incomplete EHR medication orders on the automation of 
RxNorm coding/mapping was analyzed. 
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1.2 Background 
Diverse medication vocabularies are used to improve the semantic interoperability 
between electronic health records (EHRs). For example, a Computerized Physician Order 
Entry (CPOE) or a Pharmacy Information System (IS) might use a local terminology or 
provided by a vendor or both [26]. When a medication order s submitted by the provider, 
it gets to the electronic Medication Administration Record (eMAR), medication names 
will probably be modified to match the package description at the Food and Drug 
Administration (FDA)’s National Drug Code (NDC) level [27]. Consequently, it is likely 
that the same medication concept can be linked to more than one identifier.  
In 2004, the initial release of RxNorm was created as a mean to provide an available and 
reliable standard medication terminology to mediate messages between systems not using 
the same software and vocabulary. Eventually, this will improve the semantic 
interoperability of information in heterogeneous systems. [28,29].  
There have been several studies that mapped medication terminology across institutions 
prior to the development of RxNorm. For example, Kannry et al. [30] conducted a study 
in 1996 to examine the issues involved in mapping an existing structured controlled 
vocabulary, the Medical Entities Dictionary (MED) developed at Columbia University, to 
an institutional vocabulary, the laboratory and pharmacy vocabularies of the Yale New 
Haven Medical Center. With a match rate of 73%, the researchers highlighted the critical 
need of standardization of local pharmacy vocabulary subsets, standardization of attribute 
representation, and term granularity. 
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In another study, Sherertz et al. [31] utilized a lexical mapping that matches terms on an 
“exact word by word equivalence of phrase.” They demonstrated the approach by 
lexically mapping 834 descriptions from the University of Southern California at San 
Francisco (UCSF) to Medical Subject Headings (MeSH) [32] terms. They successfully 
mapped 47.8% of the descriptions to MeSH terms.  
Another mapping approach was proposed by Evans et.al. [33] and Cimino et.al [34]. 
Their utilized a frame-based approached for mapping descriptions and terms. A frame is a 
self- contained “unit of knowledge representation” that contains a term and its attributes. 
The mapping approach identifies semantic and hierarchical relationships between terms. 
In both studies a match rate of 40% to 50% was achieved. 
Mapping studies that utilized algorithms and tools prior to the existence of RxNorm are 
in general small in size; i.e. the number of mapped terms is usually below 1000 terms. 
This is due to the fact the mapping algorithms relied heavily on manual interactions that 
make it a very time consuming process. Furthermore, the match rate is usually <50%. 
This is referred to incomplete information that impacted the mapping. For example, 
Kannry et al. [30] reported that many extracted pharmacy terms do not specify values for 
the attributes dose and dosage in advance. 
With the development of RxNorm and given its emerging role as a national standard, its 
use within the informatics infrastructure of many organizations was felt to offer a 
scalable strategy for representing drug orders obtained from different EHR systems using 
different drug vendor information models. A study in 2009 by Hernandez et.al. [35], 
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merged pharmacy data from two Stanford hospitals that use different drug representation 
systems into a single, standards-based model supporting research by mapping HL7 
pharmacy orders to RxNorm concepts, the output was utilized by the Stanford 
Translational Research Integrated Database Environment (STRIDE) clinical data 
warehouse.  Compared to the studies conducted prior to the development of RxNorm, we 
notice that this study mapped around 9000 pharmacy orders and achieved a mapping rate 
of 93%. The matching rate was impacted by the data quality of the text and as a result 
manual mapping was required in some cases.  
RxNorm was also used to exchange standardized, codified patient drug allergy 
information between VA and DoD [36].  RxNorm is designated as the national standard 
for exchanging allergies to branded drugs. After both agency files were mapped to 
RxNorm, DoD will understand 74 percent of VA terms and VA will understand 58 
percent of DoD terms. One major drawback identified in this study for using RxNorm is 
that RxNorm is not built to be a complete drug reference terminology. As a result, it does 
not model drug classes and multiple ingredient generics (which make up a portion of the 
drug allergies file in both agencies) as single terms.  
RxNorm has been as well used to capture medication history of the patient. Two methods 
have been usually used to capture patient’s medication history:  
Mapping patient’s medical data into RxNorm after the data is being collected. Most of 
the studies in this domain achieved a certain percentage of medications map correctly and 
usually a manual interaction is needed. In addition, many successful mapping efforts have 
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been limited to well-defined subsets containing only fully specified prescriptions 
incorporating National Drug Codes (NDCs) [37].  Even the most sophisticated algorithms 
cannot overcome all the limitations of poorly collected medication history at the point-of-
care, such as open-ended free text fields, non-standard abbreviations, or invalid 
combinations due to uncontrolled data capture (e.g., recording a medication in a non-
existent dose unit or dose form) [38]. 
Capturing patient’s medication data in RxNorm-compatible format at the point of data 
entry. While this approach avoids some of the issues that the above approach faces, it still 
has its own challenges. For example, medication coverage can be an issue if a medication 
is missing in a search list which may prevent data entry from occurring. In addition, data 
entry systems must allow the capturing of partial data when the patient does not recall 
specific information or lacks the abilities to report complete information (e.g., an 
individual experiencing psychotic schizophrenia) [38, 39]. 
In general, mapping medication information to terminology standards is a challenging 
process due to many reasons [23, 40, 41]: 
• The drug naming conventions as well as drug attributes are represented differently 
among institutions, or even among various applications (e.g., CPOE, Pharmacy 
IS).  
• The various representations of drug names (e.g., ingredient name, generic name, 
multiple brand names, and longstanding “nicknames” like HCTZ that means 
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hydrochlorothiazide and APAP that stands for acetaminophen). This yields a 
number of mappings for one term. 
• The incompleteness and various representations of drug signature elements (e.g., 
dose form and strength information), yielding a number of mappings for one term 
(e.g., “Acetaminophen 325 MG / Oxycodone Hydrochloride 5 MG Oral Tablet 
[Percocet 5/325] ”).  
• The maintenance of mapping results is another challenge. With the regular 
updates to terminologies (e.g., addition, refinement, and obsolescence), the 
mapping results needs to be maintained and updated as per the new releases of 
terminology standards. Consequently, the initial mapping effort might not be 
sufficient. Continuous maintenance of the mapping results might be needed.  
• The mapping effort becomes costly and time consuming, if only using approaches 
that rely heavily on manual interactions. An automated method would make the 
process manageable and allow institutional dictionaries to stay “in synch” with 
the standards.” [42]. 
Little research has been done to study the mapping between RxNorm and medication 
terminologies developed at local institutions or other organizations [36]. Further analysis 
is needed to understand the underlying data issues that impact the mapping rate and to 
identify recommendations to enhance mapping rates. Such studies are critical for the 
future adoption and integration of RxNorm in EHRs [42]. 
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Chapter 2 – Research purpose and methods 
2.1 Research Purpose  
The main goal of this study was to evaluate the impact of incomplete EHR medication 
orders on the automation of RxNorm coding/mapping. Specifically, the research question 
is: how to develop a semi-automated mapping process for incomplete EHR medication 
orders using existing RxNorm API?   
To answer the research question, the following specific objectives were addressed: 
• Describe EHR issues that affect the ability to automate mapping of medication 
records to RxNorm.  
• Map EHR medication records that have missing National Drug Codes (NDC) to 
RxNorm. 
• Create a list of rules to enhance automated RxNorm coding (help finding the most 
accurate target RxNorm concept without manual review) of EHR medication 
based on observations from the manual review step.  
• Validate the set of rules by applying the set of rules to RxNav API for all EHR 
medications and compare results to Medi-Span® coding tool.  
• Describe data quality issues that may affect mapping medication orders to 
RxCUIs. 
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2.2 Data Source 
In this study, about 25 million medication orders with missing NDCs were analyzed.  The 
source data was from the Academic Health Center Information Exchange Platform at the 
University of Minnesota (AHC-IE). The AHC-IE is a secure environment to hold 
protected health information provided by the Clinical Translational Science Institute, 
Biomedical Informatics (CTSI-BMI) and managed by the Academic Health Center 
(AHC) at the University of Minnesota. AHC-IE contains clinical data from Fairview 
Health System’s (FHS) EHR with data from 8 hospitals and over 40 clinics. The AHC_IE 
platform [43] is shown in Figure (1).  
 
Figure 1 - The Academic Health center Information Exchange Platform at the University of Minnesota 
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The details associated with de-identified medication orders were extracted and provided 
in an Excel file for the investigator. The medication orders where then filtered to exclude 
RxNorm out-of-scope items. This covers radiopharmaceuticals, bulk powders, contrast 
media, food, dietary supplements, and medical devices, such as bandages and crutches. 
This resulted in approximately 20 million records.  
The most frequent medications without NDC codes covered approximately 95% of the 
EHR medication orders, which represents around 4000 records, were considered for the 
purpose of the RxNorm mapping effort. The medications were mapped to RxNorm using 
RxNav; which is a browser and Application Programming Interfaces (API) for RxNorm 
provided by NLM to resolve drug information into an RxNorm concept [44]. 
2.3 Methods 
This work was exempt from the Institutional Review Board (IRB) approval since the data 
utilized were sufficiently de-identified. The analysis was performed using a 
secure, HIPAA-compliant environment. 
The automated mapping results were manually reviewed by a registered pharmacist 
(RPH) under the supervision of a registered nurse (RN) and a medical doctor (MD) to 
create a gold standard. To validate and further refine the gold standard, we ran the same 
set of medications (pertained to 95% of the EHR medication orders) through Medi-Span 
tool and results were compared to the manual review results. We evaluated the accuracy 
of the automated mapping by comparing the results of RxNav to the gold standard. 
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2.3.1 Framework  
We followed a framework similar to Zhou, et. al’s. study design where they measured the 
accuracy of an NLP-based approach for RxNorm coding [42]. While the study 
framework is similar, we customized it to fit the aims of this research (Figure 2).  
 
Figure 2 - RxNorm Coding Framework 
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2.3.2 Data Extraction and Preparation 
There were a combination of 19033 unique medication names and signatures without 
NDC codes representing 24,994,195 medication orders extracted using a SQL query from 
Clarity tables and were listed in a descending order according to the count of medication 
orders. The query pulls the data fields described in Table (2) from the landing zone of the 
AHD-IE data warehouse in which EPIC Clarity data are loaded. The fields were selected 
to match the format of the normalized drug name in RxNorm standard; which consists of 
name, active ingredient, strength, dose, form and route. 
Table 2 - Extracted EHR medication order dataset 
Field Name Description 
Medication ID The unique ID of the medication record. 
Name 
The name of the medication. It could be generic, brand 
or a general name. 
Form 
The form of the medication, such as tablet or 
suspension. 
Route 
The route of administration of the medication, such as 
intramuscular or subcutaneous. 
Strength 
The strength of this version of the drug, for example, 
10%, or 50 mg/ml. 
Med_order_count 
Added field to count the frequency of the Med_ID 
appeared in the table. 
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An expert (Pharmacist) manually filtered the extracted list of medications to exclude 
medications that do not map to RxNorm as per RxNorm exclusion criteria. This includes 
radiopharmaceuticals, bulk powders, contrast media, food, dietary supplements, and 
medical devices, such as bandages and crutches, which are all out of scope for RxNorm 
[12].  
Consequently, 1,010 (5.3%) unique medication identifiers pertained to 5,437,573 (21.1%) 
medication orders were excluded from the list of 19,033 unique medication identifiers. 
The list of medications now contains 18,023 records representing 20,556,815 medication 
orders. 
We further manually filtered the list of medications, for the RxNorm mapping effort, to 
focus on the most frequent medications identifiers; which we define as medication 
identifiers that are related to 95%, Figure (3) displays a chart that illustrates the 
cumulative count f the medications when sorted in a descending order according to their 
occurrence frequency in Clarity tables.  
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Figure 3 - Cumulative frequency of medication records showing the 95% cut point 
 
The resulting list contained 3713 medication identifiers representing 18,578,791 EHR 
medication orders. This covers the top 3713 medications from the list of medications that 
are arranged in a descending order according to the count of the medication orders per 
medication identifier.  
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2.3.4 RxNorm Coding of EHR Medications 
Initially, the RxNorm coding effort of the identified 3,713 medications started manually 
(849 medications) and then was automated to speed up the process (2,864 medications).  
 
2.3.4.1 Manual Mapping using RxNav Explorer 
Mapping of 849 medication records was done manually using RxNav Explorer; an NLM 
tool for mapping drugs to RxNorm standard using a Java Web Start Technology [45]. 
Figure (4) shows a snapshot of RxNav explorer results screen. 
 
Figure 4 - RxNAV Explorer search results screen 
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We used the string-based search process of the Explorer. The process requires manual 
data entry of medication name as well as signature information. The available provided 
information determines whether a specific RxNorm mapping can be found. If any of the 
signature information is missing, then expert intervention is needed to select the most 
appropriate RxNorm code from the Explorer’s list of suggested Target RxCUI. In this 
case, the selected RxCUI would represent a less specific drug mapping as in the example 
in Figure (5). 
 
Figure 5 - List of RxCUI mapping options retrieved by RxNAV for a medication with incomplete information 
In some cases, the medication information would need to be edited prior to mapping to 
RxNorm. For example (Figure 6), RxNav would not map “SULFATRIM DS 800-160 
MG OR TABS” to RxNorm since it does not recognize the format of the medication. 
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Figure 6 - RxNAV may not recognize original medication strings 
The medication Information was adjusted to SULFATRIM only for the medication name. 
The remaining medication information was manually entered by an expert (Figure 7).  
 
Figure 7 - Editing of original medication information needed to find a mapping result. 
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2.3.4.2 Automated Mapping using RxNav API 
To speed up the process, we moved toward a semi-automated process in which a Java 
program has been created to utilize the RxNorm API web services for accessing the 
RxNorm data set [46]. The Java code workflow is illustrated in Figure (8).  
 
 
Figure 8 - Automated mapping workflow using RxNorm API 
 
Text Normalization Using RxNorm API: 
 Using the lexical variant generation Norm (referred to lvg-norm) module of the RxNorm 
API tool, the normalization process involves stripping genitive marks, transforming 
plural forms into singular, replacing punctuation (including dashes) with spaces, 
removing stop words, lower-casing each word, breaking a string into its constituent 
words, and sorting the words in alphabetic order [47]. In addition, some 
standard abbreviations and acronyms are expanded into full names [48].  
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Exact match:  
Using findRxCUIByString functionality of the RxNorm API tool, 
(http://rxnav.nlm.nih.gov/RxNormAPIs.html#uLink=RxNorm_SOAP_findRxCUIByStri
ng), the Exact match process finds a matching record in RxNorm database for the exact 
given post-normalization drug name passed to it. 
 
Approximate match:  
If the exact match process fails to find a matching RxCUI for the passed drug 
information, then the process will route the medication name and other information to the 
approximate match functionality of the RxNav API; ‘getApproximateMatch’ which does 
an approximate match search to determine the strings in the RxNorm data set that most 
closely match the search string. This function finds the closest matches of the string with 
drug name concepts in RxNorm. Strings containing other medical terms such as drug 
classes or diseases will yield little or no results since the algorithm looks for drug names 
in the string. (http://rxnav.nlm.nih.gov/RxNormApproxMatch.html). An approximate 
match group structure also contains RxCUI, a score; calculated by Jaccard’s coefficient 
and ranging from 0 to 100 indicating the closeness of the match, and a rank of the string 
to all possible candidates [47]. 
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2.3.4.3 Manual Review of Automated Mapping Results 
The results of the automated mapping need to be reviewed by an expert to identify the 
most appropriate RxCUI to be used for each drug. Domain experts need to interactively 
monitor the process and help facilitate text processing steps, especially in critical 
domains like healthcare [49]. In addition, during this process, we tag each mapping result 
with a justification of why a specific RxCUI was selected.  
 
2.3.5 Mapping Rules Identification 
During the manual review of automated mapping results and the selection of the most 
appropriate target RxCUI concepts, clinical domain experts identified a set of business 
rules that can help enhance coding automation.  
 
Some of these rules were based on observations while others were based on clinical 
knowledge. The following summarize the most important rules agreed upon: 
• Map to the most granular RxNorm code available that matches the information 
provided.   
• Map to the brand name if it was mentioned since brand names give more specific 
information about the medication.  
• If no brand name is mentioned then map to the generic name. Don’t add brand 
names even if there is no generic product available in the market.  
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• When the strength is not known, map to the form and route (ex. Oral tablet). 
Don’t map to any strength even if there is only one strength savialbe in the market 
or if it is the most commonly used one unless its impeded within the name of the 
medication. 
• If the form is not known, then map to the form group. (ex. oral product).  
• When the form and the strength are not mentioned, map to the active ingredient. 
 
2.3.6 Rules Validation 
The goal of this step is to validate the correctness of the identified business rules. The 
ultimate objective is to validate the accuracy of selected RxCUI and minimize manual 
intervention by an expert. 
To perform the validation process, the business rules identified in the previous step were 
applied and the automated mapping was executed on the remaining EHR medication 
orders. The output was then compared to the output of the Medi-Span mapping tool. 
Medi-Span is a tool used by Fairview (the provider of the EHR medication orders) to 
map Medication orders to the appropriate RxNorm concept.  
We used medication GPIs (Generic Product Identifiers) to match Medi-Span mappings 
with mappings produced by RxNav (automated mapping with business rules applied).  
GPI is a common medication identifier for both Medispan and Clarity medications, which 
is considered a more accurate info than the medication name. Medication Orders were 
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then matched on the GPI and then imported along with their accompanied RxCUI from 
RxNAV and Medispan into table RZ_CODE_MAP_OPTION. 
Any medication with the same GPI and different RxCUI is considered a mismatch 
between the Medi-Span mapping output and the automated RxNav mapping (with 
business rules applied). The discrepencies were then analyzed and justified. Finally, one 
RxCUI per EHR medication is selected. 
 
 
Chapter 3: Results 
3.1. Data Quality 
3.1.1 Data Completeness Analysis 
An export was generated of the medications that were missing NDC codes. Each 
medication ID was exported with its accompanying record identifier; generic name, form, 
route, and strength. When analyzing the data, it was found out that many records are 
missing one or more of its specifications; strength, route, form. This, in many cases, 
might direct the mapping to a more general term. Table (3) shows the difference in 
mapping two different records with complete and missing information, correspondingly. 
Mapping to a more general term will result in getting incomplete information about the 
medication the patient is taking and hence this does not satisfy study objectives for 
researchers. More about this challenge will be deliberated in the discussion section. 
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Table 3 -RxNorm mapping results for a medication with complete VS missing information 
Medication specifications RxCUI RxNorm name 
Metoprolol succinate ER 25 
mg tab 
866427 
24 HR metoprolol succinate 25 MG 
Extended Release Oral Tablet 
Metoprolol po 1163523 
Metoprolol Oral Product 
 
 
Table (4) shows the completeness of the EHR medication records that were used in this 
research. The results in the table below reveal that records with missing form and 
strength represents 57.9 % of the records which have the highest occurrence rate. On the 
other hand, only 34.1% of the medication orders records have all four specifications 
available filled in their designated fields.  This means that 65.9 % of the records are 
missing one or more of the product identifiers. Another observation from this table is that 
the form is usually available with a rate of more than 99%.  
 
Table 4 - Analysis of the completeness of EHR medication records in Clarity tables 
Missing Information Count Percentage 
Form only 2 0.05 
Route only 1 0.03 
Strength only 239 6.44 
Form and Strength 2150 57.90 
Form and Route 0 0.00 
Route and Strength 0 0.00 
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Missing none 1266 34.10 
Missing All 55 1.48 
Total 3713 100 
 
 
 
3.1.2 Pharmacological Drug Groups 
 A drug is usually classified either by the chemical type of the active ingredient or by the 
way it is used to treat a particular condition. Each drug can be classified into one or more 
drug classes. Table (5) clarifies different drug classes covered by the database.  
Table 5 - Major pharmacological drug groups covered by the dataset 
Pharmacological group Examples 
Gastrointestinal tract/ 
metabolism 
Antacids, Laxatives/Antidiarrhoeals, Anti-diabetics, 
Vitamins/Dietary minerals 
Blood and blood 
forming organs 
Antithrombotics, Antiplatelets, Anticoagulants, 
Antifibrinolytics, thrombolytics/fibrinolytics,  
Cardiovascular system 
Cardiac therapy/antianginals, Antihypertensives, 
Antihyperlipidemics  
Skin Emollients, Antipruritics, Antipsoriatics, Medicated dressings 
Genitourinary system 
Hormonal contraception, Fertility agents, SERMs, Sex 
hormones 
Endocrine system 
Hypothalamic-pituitary hormones, Sex hormone, Thyroid 
hormones/Antithyroid agents 
Infections and 
infestations 
Antimicrobials, Vaccines 
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3.2 Mapping Results  
Table (6) demonstrates the ability of the automated mapping approach (using Exact or 
approximate match) followed by the manual review by an expert for the list of retrieved 
mapping results. The results show a 72.6% (Category 1- table 9) right map for Clarity 
medications to RxNorm. On the other hand, 2.9% of the medication records are missing 
some specifications; hence we had to map the medication record to RxNorm concept that 
has the same level of granularity to avoid adding extra information than given.  
 
 
Malignant disease Anticancer agents, Antineoplastic 
Immune disease Immunomodulators, Immunostimulants, Immunosuppressants 
Muscles, bones, 
and joints 
Anabolic steroids, Anti-inflammatories, NSAIDs, 
Antirheumatics, Corticosteroids, Muscle relaxants, 
bisphosphonates 
Brain and nervous 
system 
Analgesics, Anorectics, Anti-ADHD , Anticonvulsants, 
Antidementia Antimigraine , Antiparkinson's , 
Antipsychotics, Anxiolytics, Depressants 
Euphoriants, Hallucinogens, Psychedelics 
Hypnotics/Sedatives 
Respiratory 
system (R) 
Decongestants, Bronchodilators, Cough medicines, 
H1 antagonists 
Sensory organs (S) Ophthalmologicals, Otologicals 
Not covered 
Antidotes, Anesthetics ,Contrast media, Radiopharmaceuticals 
Dressings 
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Table 6 : Mapping results according to the closeness of the RxCUI to the medication information offered from 
EHR. 
Category Implication 
Medication records 
N % 
1 
Exact match was found 95 3.2 
72.6 The RIGHT RxCUI was selected from 
the retrieved list of APPROXIMATE 
match options  
2134 69.4 
2 
The RIGHT RxCUI was not found by 
exact and approximate mapping. The 
RIGHT RxCUI was found 
MANUALLY 
262 8.9 
3 
The CLOSEST* RxCUI was selected 
from the retrieved list of 
APPROXIMATE match options 
75 2.6 
4 
The CLOSEST* RxCUI was not listed 
within the retrieved option and was 
found MANUALLY 
8 0.3 
5 No RxCUI was found 233 7.9 
6 
RxCUI selected represents a very 
general term.  
227 7.7 
  Total 2939 100.00 
*Closest match means that there is a slight difference between the RxCUI description and the medication record 
information. For example, Vitamin D3 2000 oral tablet and oral capsule. 
Table (7) presents the reasons for incomplete or missing match (category 5 and 6). This 
can be attributed to differences in dosage, strength, and route form. Various issues 
regarding deficient mappings for drug concepts were identified. 
Table 7 : Examples of reasons that some records were not mapped to a valid RxCUI or mapped to  very general 
term. 
Reason Example 
Obsolete term, term is no longer 
used. 
ZICAM COLD REMEDY NA; recalled product 
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3.4 Validation Using Medispan 
After comparing RxCUIs generated by Medispan and the automated RxNav mapping 
(with business rules identified), a spreadsheet was then generated 6,809 medication 
records that had been mapped to codes that the Medi-Span file disagrees with.  Most of 
these are simple things like Medi-Span file chose the generic over the brand name See 
table (8) for a List of discrepancy reasons.  A researcher (SA, RPh) reviewed this 
Cosmetic 
VANICREAM EX; cosmetic product are not 
covered in RxNorm even if they are used for a 
medical condition Ex dry skin or eczema 
OTC not in RxNorm 
HEALTHY COLON PO, LIPOFLAVONOID 
PO 
Too complex name GLUCOS-CHONDROIT-CA-MG-C-D PO 
Unclear ingredient / unclear 
name 
JOINT FORMULA OR 
Unavailable strength or name 
SENNA HERBAL LAXATIVE 50-12 MG OR 
CAPS 
Compounds 
MAGIC MOUTHWASH (DUKE) (FV 
COMPOUNDED) SUSPENSION, 
GABAPENTIN 8%/ 
VANICREAM (FV COMPOUNDED) CREAM 
Unavailable form-ingredient 
combination 
VITAMINS B1 B6 B12 IJ INJ; This 
combination is only available as oral product not 
injectable 
Missing one or more of the 
active ingredients 
NEOMYCIN-POLYMYXIN (OTIC) SUSP   
OT; this product does not exist, it should be 
Hydrocortisone / Neomycin / Polymyxin B Otic 
Suspension. Hence it’s missing the 
hydrocortisone part.  
Some herbal products 
GLUCOS-MSM-C-MN-GINGER-WILLOW 
PO,  HERBAL ENERGY COMPLEX PO 
Miscellaneous 
Mouth wash, NONI JUICE PO,CHOLEST OFF 
COMPLETE PO 
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spreadsheet and selected the more accurate choice among the results generated from the 
semi-automated process and Medi-span mapping. Table (9) shows the results of this 
validations process. More than three thirds (75.9%) of the preferred RxCUIs were 
generated using the auto mapping approach.  
 
 
Table 8 : List of reasons for the discrepancies between RxCUI generated by Medisapn and RxNAV API. 
Reason 
Medication 
Name 
Auto-mapping 
Result 
Medi-Span 
Mapping Result 
Medispan added 
more 
information than 
given 
CALCIUM + D 
PO 
Calcium 
Carbonate / 
Cholecalciferol 
Oral Product 
308896 - Calcium 
Carbonate 250 MG 
/ Vitamin D 125 
UNT Oral Tablet 
Medispan chose 
generic name 
while auto-
mapping chose 
brand 
 
NASONEX 50 
MCG/ACT NA 
SUSP 
746201-120 
ACTUAT 
mometasone 
furoate 0.05 
MG/ACTUAT 
Nasal Inhaler 
[Nasonex] 
746199 - 120 
ACTUAT 
mometasone 
furoate 0.05 
MG/ACTUAT 
Nasal Inhaler 
Medispan 
Specifies 
quantity that is 
not mentioned 
FLUTICASONE-
SALMETEROL 
250-50 
MCG/DOSE IN 
AEPB 
Fluticasone 
propionate 0.25 
MG/ACTUAT 
/ salmeterol 
0.05 
MG/ACTUAT 
Dry Powder 
Inhaler 
896186 - 14 
ACTUAT 
Fluticasone 
propionate 0.25 
MG/ACTUAT / 
salmeterol 0.05 
MG/ACTUAT Dry 
Powder Inhaler 
Auto added 
brand name 
when not 
mentioned 
FLUOXETINE 
HCL 20 MG PO 
CAPS 
Fluoxetine 20 
MG Oral 
Capsule 
[Prozac] 
310385 - 
Fluoxetine 20 MG 
Oral Capsule 
Different form 
MECLIZINE 
HCL 25 MG PO 
Meclizine 
Hydrochloride 
995666 - 
Meclizine 
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TABS 25 MG 
Chewable 
Tablet 
Hydrochloride 25 
MG Oral Tablet 
Auto is missing 
one component 
NYSTATIN 
100000 
UNIT/GM EX 
POWD 
Nystatin 
Topical 
Powder 
Nystatin 100 
UNT/MG Topical 
Powder 
 
Table 9 : Validation findings when comparing results generated by Medisapn and RxNAV 
RxCUI selected 
Source 
Number of 
records from 
the selected 
source 
Percentage of records 
that are linked to the 
correct RxCUI 
Auto Mapping 5170 75.9 % 
Medispan 1518 22.3 % 
Not found,  
needed manual 
mapping 
121 1.8 % 
Total  6809 100 % 
 
In this study, the most granular RxCUI available was chosen when mapping the 
medication record.  For example, brand name is a more precise approach of naming any 
medication because it limits the number of NDCs and thus the number of RxCUIs to 
choose from. Hence, choosing an RxCUI that specifies the brand in addition to the 
generic name was considered to be an accurate selection when mapping branded name 
medications. Nevertheless, integrating a brand name to the concept would be an 
unnecessary addition to a medication name that does not specify a brand, even when 
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there is no generic product available for that medication during the time the study was 
conducted.  
 
Chapter 4: Discussion & Conclusion 
4.1 Discussion 
This study involved enhancements to automated mapping approach to map 3713 unique 
medications with incomplete medication information (used by about 19,560,024 
medication orders) to RxNorm using RxNorm API. The automated mapping was 
enhanced by the addition of mapping rules that were identified by a researcher (SA, RPh) 
and then validated by comparing RxNav results to mapping results created by another 
mapping tool (Medi-Span). In this study, it was found that the total success rate of 
mapping medications with incomplete information to the correct RxNorm concept equals 
to 72.6%. The matching rate becomes 87% when mapping results of 53,000 medications 
using the automated approach were compared to the mapping results of Medi-Span tool; 
which was used to validate the study approach. It is anticipated that the enhanced 
automated mapping approach would support health information exchange and medication 
reconciliation process.  
For the extracted medication orders with missing medication NDC, it was found that 
65.9% of these records were also missing one or more essential medication information. 
In any EHR system, the medication information completeness varies at the point of 
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medication order entry to meet various purposes, including but not limited to, inpatient 
medication order entry, pharmacy inventory, and checking duplication of therapy and/or 
drug allergy [63#50]. For example, when checking drug allergies it is adequate to record 
the medication name without the strength or form since a patient will be allergic to the 
active ingredient regardless of the form or strength i.e. penicillin allergy. However, when 
stocking up a medication for a pharmacy inventory, it’s important to record all 
specifications of the medication including form, strength, and package size. 
 
Previous studies have shown that the incompleteness of drug signature elements yields a 
number of possible RxNorm mappings for the same medication.  The mapping effort in 
this case becomes costly and time consuming since it relies heavily on manual expert 
interactions. The studies state that an automated method would make the process 
manageable especially for the mapping of large number of medications [23, 40, 41]. 
 
When using the automated mapping approach, it was found that only 3.2% of Clarity 
records included in this study can be directly mapped to one exact match in RxNorm that 
can be identified using the exact match approach. These medication orders already came 
with enough information that can be used to identify one RxNorm concept. In addition, 
about 69.4% of the medications in this study utilized the approximate matching approach 
to identify the correct RxNorm concept utilizing the identified business rules. This made 
the total success rate of the medications that were able to correctly identify a matching 
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RxNorm concept equal to 72.6%. Prior to the development of RxNorm, several pharmacy 
system knowledge base vendors embarked on an attempt to match terms across different 
terminologies and had a 53% success rate [51]. Better success rate was reported by other 
studies when medication orders with data issues were excluded for the mapping effort 
[62#36, 58#35]. These studies addressed challenges such as the inclusion/exclusion of 
salts, different representations of strength, and naming conventions. The studies also 
reported that further analysis is needed to understand the underlying data issues that 
impact the mapping rate and to identify recommendations to enhance mapping rates. 
Such studies are critical for the future adoption and integration of RxNorm in EHRs [42, 
36]. 
 
Compared to our approach of using mapping rules to enhance automated mapping, 
previous studies focused on using a completely manual approach for the mapping of 
medications with missing information. One of these studies provided by Saitwal et 
al. [5] provided a methodological review of twelve terminological systems highlighting 
how medication information is distributed across these systems and how they are linked 
through common codes. In their study, only 62.5% of source medication codes could be 
mapped automatically. The medications with missing information were mapped using a 
completely manual approach, which as mentioned above is very time and effort 
consuming.  
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The majority of the medication orders had several issues that required going through the 
approximate match process. Some of these issues include, not specifying the active 
ingredient of the product, for example, COLON HEALTH PO. In addition, the 
medication name may contain multiple ingredients that are too complex to be mapped to 
a specific RxCUI such as different types of multivitamins. In such a situation, manual 
intervention was required to map the medication term to a more general term to minimize 
the number of records that do not map to any precise RxCUI. When the medication 
record, COLON HEALTH PO was further inspected, it was found that the active 
ingredient is lactobacillus and was mapped to LACTOBACILLUS ACIDOPHILUS 
ORAL PRODUCT. In this way, the med record was mapped to a relevant concept and 
distinguished from other unmapped records, however, it would take extra time and effort 
from the researcher to investigate the product’s active ingredient, which might be 
inconvenient and expensive for research purposes. 
  
Relative contribution of each component of the automated mapping process such as name 
splitting, drug name expansion, spelling correction and using the identified business rues 
all helped in finding a match to the targeted concept. For example, RxNorm did not 
recognize “LEVOTHYROXINE SODIUM 88 MCG PO CAPS”; the name had to be 
expanded to the following term “LEVOTHYROXINE SODIUM 0.088 MG ORAL 
CAPSULE” so it can be read flawlessly by RxNorm.  
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The identified business rules were also able to address some of the medication 
information issues for the support of automated mapping. One of these helpful rules was 
mapping drug names with missing strength and/or form information to a short name. For 
example, when looking for “POTASSIUM GLUCONATE PO”, the strength and form 
were overlooked and the medication record was mapped to “POTASSIUM 
GLUCONATE ORAL PRODUCT” which matches the level of granularity of the 
medication term in the dataset. 
 
In addition, mapping to the active ingredient was one of the identified business rules for 
mapping medication orders that did not have a specific strength, route, or form. For 
example, SIMVASTATIN was mapped to RxNorm name SIMVASTATIN. This 
approach helped classify drugs under their therapeutic class hierarchy instead of leaving 
it unidentified. Consequently, it helps researches identify patients with hyperlipidemia 
from hypertensive or diabetic patients, identify duplication in therapy, detect drug-drug 
interactions in poly-pharmacy patients, or determining DEA scheduling of the recorded 
medication. 
 
Another business rule that has several benefits is mapping medication orders to   RxNorm 
concepts that are associated to a slightly different term from the original record name in 
the database. Those minor differences should make no significant influence on the 
intended medication action or use. For example POLICOSANOL TAB 10 MG was 
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mapped to RxNorm concept POLICOSANOL 10 MG ORAL CAPSULE that only differs 
in the form type. This helps identify the active ingredient, strength and route, which are 
the most vital pieces of information for any medication especially in inpatient order 
entries. 
 
The results of the validation process illustrated that the identified business rules can be 
used to enhance the automated mapping process. For 53,000 medications, there was an 
87% matching rate in the identified RxCUI generated by both the automated process 
(with business rules applied) and the Medi-Span tool. For the records that have different 
mapping results by the automated process and Medi-Span, the expert (SA, RPh) manual 
review found that about 75.6% of the times the correct mapping results were actually 
identified by the automated process with the business rules applied. One of the reasons 
behind the mismatch between the automated process and Medi-Span is that there were 
some invalid RxCUIs that were used by Medispan but actually are no longer used by 
RxNorm. In RxNorm, some dosage forms have been retired and replaced by more 
generic dose form names, allowing for greater flexibility in representing drug names. 
Other dose forms have been added. At this time, manual review was the only way to 
check the validity in the RxCUIs used when a discrepancy was revealed. 
Another reason for mismatch between the automated approach and Medispan was that 
Medispan selected branded name RxCUIs over generic ones where the original name in 
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the dataset did not specify any brand name. Instead, the automated mapping only mapped 
to the brand name if it was declared within the record name itself or it’s specifications.  
The following points explain some cases where choosing brand name for mapping 
purposes over the generic is preferred if, and only if, the brand name is provided:  
• Brand name provides a more specific level of granularity (just second best after 
NDC). For example, “Lantus Solostar” is the brand name for the only available 
product of the active ingredient Insulin Glargin in a flex pen injectable form. 
Hence from the brand name we can obtain the exact NDC and map it to the exact 
match RxCUI. However, this would need an expert opinion to tell if there is one 
ingredient/route/form/packaging combination or more with the same brand name.  
• Specifying the brand name reduces the number of RxCUIs generated to select 
from. For Example Spiriva comes in one strength/form/Route combination, 
however it comes in two different package sizes; 30 caps and 90 caps. So between 
those 2 options it would be safe enough - most of the times- to map the source 
medication to either one.  
• Some brands are not bioequivalent Despite having the same 
strength/form/route/active ingredient combination. For example “Synthroid 25 
mcg po tab” is not interchangeable with “ Levoxyl 25 mcg po tab” although both 
of them have the same active ingredient; levothyroxine sodium or LT4. [52] 
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Brand versus generic always play an important role in the formulary list. Many brand 
names are not covered, not preferred or would need prior authorization from the 
insurance company to approve its coverage if proved to be medically necessary.   
The findings of this study not only illustrate the applicability of RxNorm standards to 
coding medications used in the CDR database for clinical research, but also identified 
multiple issues related to recording and processing of medication information that would 
need to be addressed in order to facilitate building and deploying interoperable electronic 
health record systems. 
Previous studies reported that the analysis of EHR medication data issues is critical for 
the future adoption and integration of RxNorm in EHRs [42,36]. This study analyzes 
large number of EHR medication orders with the focus of identifying issues, analyzing 
the impact to RxNorm mapping and describing an approach that can be used to enhance 
the automated mapping. RxNorm concepts have been utilized for coding clinical 
medication data in many clinical research studies and applications. However, there are 
very few studies that analyze the underlying reasons of the EHR medication order data 
issues and the impact to RxNorm mapping. It is anticipated that this study will enrich the 
literature with a large EHR medication order analysis. The results of this study are 
expected to lead to better clinical research studies and applications that utilize RxNorm 
concepts. Ultimately, this will enhance health care quality and reduce healthcare cost. It 
is also anticipated that the results can be used to identify more business rules or refine 
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current ones to design a more robust rule-based system for the support of automated 
mapping tools with minimal human intervention.   
  
4.2 Limitations 
This section covers few limitations that were encountered during this study. Some were 
related to RxNorm and some related to the Clarity Database. Generalization of our 
findings may be impacted as a result of these limitations. 
RxNorm is intended to cover all prescription medications approved for use in the United 
States. Prescription medications from other countries may not be correctly mapped to 
RxNorm concepts. The same also applies to some Over-the- counter (OTC) medications. 
RxNorm are currently analyzing the opportunities to add and cover OTCs when reliable 
information about the medications can be found and when they appear to be represented 
in other UMLS source terminologies. If a medication source is out the designated source 
vocabularies included in RxNorm then the medication will not be mapped to a valid 
RxCUI. In addition, medications with more than four ingredients, whether prescription or 
OTC, are not fully represented at the present time. In some cases (e.g., multivitamins) it 
may not be possible to include all of them in a reasonable time frame.  
Comprehensive terminology mapping evaluation process may require significantly more 
time, effort, and terminology-specific expertise than can be predicted at the start of a 
project. Because these systems continue to evolve, ongoing use of any cross-terminology 
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mappings must also include a plan to accommodate these changes, such as occurs when 
codes are given different meanings, removed from a system, or new codes are added. 
 
4.3 Future Work 
To address these challenges in future work, we need to research better methods for 
automatically linking concepts across systems and maintaining these links.  
As with the case study presented here, creating new connections between systems often 
requires utilizing rule-based systems that captures experts’ knowledge and translates it 
into a programmable rule format. These rules based technique would be used to enhance 
an NLP system that is able to identify medical terms and deal with data issues as terms 
expansion. Another approach, as explored in the Galen project [22], is to provide users 
with a convenient language for logically defining the terms and relations in an ontology 
using a common reference model, followed by the application of algorithms that can infer 
conceptual mappings and class/sub- class relationships among terms from different 
source vocabularies. A combination of these approaches is worth exploring, because 
satisfactory automated approaches that do not require significant human intervention may 
not be possible without significant artificial intelligence breakthroughs. Finally, a highly 
interactive partially-automated mapping tools that are directed by human experts to 
automate parts of the mapping process with specific expert input are a promising 
alternative to fully automated methods. 
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4.4 Conclusion 
The enhanced automated mapping approach that utilizes NLM RxNav API in addition to 
the identified mapping business rules was useful for mapping the majority of medication 
records with missing information. While expert judgment is still needed, it is minimized 
by creating a short list of suggested target RxNorm concepts for the expert to pick from 
for a given EHR medication name. The study limitations suggest that a more 
comprehensive study from multiple healthcare institutes may refine the mapping rules 
identified by this study with the goal of designing a more robust system.  
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